Pharvaris (PHVS) Reports 83% Lower HAE Attack Rate Versus Placebo

Pharvaris (PHVS) reported that its drug deucrictibant XR reduced HAE attack rates by 83% versus placebo in a Phase 3 trial. The trial met all primary and secondary endpoints, with 45% of participants attack-free over 24 weeks. No serious adverse events were reported.

Original reporting
Published Nov 12, 2026, 3:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 3:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pharvaris (PHVS) Reports 83% Lower HAE Attack Rate Versus Placebo — source image
Decision brief

The 30-second read

$PHVSBullishHigh
01

Why it matters

The data represent a material clinical milestone that could accelerate regulatory filings and market adoption.

02

Market read

First report of pivotal trial results; likely to move PHVS stock and influence the HAE therapeutic space.

03

What to watch

Potential safety concerns long‑term and pricing/reimbursement challenges.

Relevance 8/10Novelty 9/10Timing: today

Background

Pharvaris released Phase 3 data for its HAE prophylaxis candidate deucrictibant XR, showing an 83% reduction in attack rate.

Company-level read

Ticker impact

$PHVSBullishHigh confidence
Context

Phase 3 CHAPTER-3 trial shows deucrictibant XR cuts HAE attack rate by 83% versus placebo.

Expected impact

upward pressure as market prices in the efficacy breakthrough.

Evidence & confidence

First disclosure of statistically significant Phase 3 results; biotech stocks typically react strongly to such news.

Market effects

Strengthens the hereditary angioedema therapeutic segment and may boost related biotech peers.

US biotech market sees fresh catalyst.

Moderate, as HAE treatments have worldwide demand.

Counterpoint

Efficacy may not translate into commercial success if regulatory hurdles or competition arise.

Key entities

  • Pharvaris

    Biotech firm developing deucrictibant XR for hereditary angioedema.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.